Here are few guesses:

1) They're sitting on the eGFR numbers to please the nephrologists and Kam KZ. They will present the numbers there and have them on their side as opinion leaders for BP or FDA. It's almost political.

2) No need to stress because it will come at the same moment as the BT Designation and maybe the next step in the direct commercialization path.

3) My guess is the incentive program is well subscribed 50-70%. I'm sure they were prepared for that. Holders of the warrants are the ones that invested in the 3$-4$ PP, RVX kool-aid drinkers.

4) I don't think it was unexpected the exit of Dr. Eldon Smith 79, for Dicky To. ORI had the option to do so. Hepalink are happy with that. You remove old blood with medical expertise, with almost no incentive to push the company to a lucrative exit to put some new blood with Tax and M&A experience with a large incentive to a lucrative exit. Trials are over and M&A is now. All is happening according to plan.